Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Bought by Janney Capital Management LLC

Janney Capital Management LLC raised its position in Structure Therapeutics Inc. (NASDAQ:GPCR) by 36.4% in the 4th quarter, Holdings Channel reports. The fund owned 9,007 shares of the company’s stock after acquiring an additional 2,405 shares during the period. Janney Capital Management LLC’s holdings in Structure Therapeutics were worth $244,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Geode Capital Management LLC raised its holdings in Structure Therapeutics by 0.7% during the third quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock worth $1,985,000 after purchasing an additional 312 shares in the last quarter. Squarepoint Ops LLC increased its position in Structure Therapeutics by 4.5% during the 2nd quarter. Squarepoint Ops LLC now owns 14,449 shares of the company’s stock worth $567,000 after purchasing an additional 617 shares during the period. Assetmark Inc. raised its stake in shares of Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after buying an additional 719 shares in the last quarter. Sandia Investment Management LP acquired a new stake in shares of Structure Therapeutics in the 2nd quarter valued at approximately $39,000. Finally, GAMMA Investing LLC boosted its stake in shares of Structure Therapeutics by 4,155.6% in the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after buying an additional 1,122 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on GPCR shares. Stifel Nicolaus assumed coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a report on Thursday, December 19th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $81.29.

Structure Therapeutics Stock Down 1.4 %

Shares of GPCR stock opened at $27.94 on Thursday. The business has a fifty day simple moving average of $30.38 and a 200-day simple moving average of $35.89. Structure Therapeutics Inc. has a fifty-two week low of $23.50 and a fifty-two week high of $62.74. The stock has a market cap of $1.60 billion, a P/E ratio of -37.76 and a beta of -2.78.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.